TrialGynecologic oncology2022

Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.

Karen Cadoo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.